KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to $105.8 million.

  • Novavax's Free Cash Flow rose 17236.19% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$383.8 million, marking a year-over-year decrease of 24626.37%. This contributed to the annual value of -$100.4 million for FY2024, which is 8692.82% up from last year.
  • Latest data reveals that Novavax reported Free Cash Flow of $105.8 million as of Q3 2025, which was up 17236.19% from -$127.7 million recorded in Q2 2025.
  • Novavax's 5-year Free Cash Flow high stood at $649.3 million for Q1 2021, and its period low was -$355.8 million during Q4 2021.
  • Over the past 5 years, Novavax's median Free Cash Flow value was -$140.8 million (recorded in 2022), while the average stood at -$69.1 million.
  • Examining YoY changes over the last 5 years, Novavax's Free Cash Flow showed a top increase of 289450.83% in 2021 and a maximum decrease of 91381.46% in 2021.
  • Quarter analysis of 5 years shows Novavax's Free Cash Flow stood at -$355.8 million in 2021, then surged by 60.41% to -$140.8 million in 2022, then tumbled by 31.8% to -$185.6 million in 2023, then increased by 5.65% to -$175.1 million in 2024, then skyrocketed by 160.4% to $105.8 million in 2025.
  • Its last three reported values are $105.8 million in Q3 2025, -$127.7 million for Q2 2025, and -$186.7 million during Q1 2025.